This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
, No Gclids
Disease Info Card
B16 Malignant Melanoma
Information about B16 Malignant Melanoma: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.
Overview of B16 Malignant Melanoma
Most recent studies have shown that B16 Malignant Melanoma shares some biological mechanisms with adenocarcinoma, carcinoma, carcinoma-lewis-lung, leukemia, leukemia-l1210, lung-neoplasms, malignant-neoplasm-of-lung, malignant-neoplasms, malignant-paraganglionic-neoplasm, melanoma, melanoma-experimental, metastatic-malignant-neoplasm-to-the-lung, neoplasm-metastasis, neoplasms, neoplasms-experimental, sarcoma, skin-neoplasms, tissue-adhesions.
Among the many pathways, these few ones have gauged particular interests from scientists studying B16 Malignant Melanoma, and have been seen in publications frequently: Angiogenesis, Cell Activation, Cell Adhesion, Cell Cycle, Cell Death, Cell Differentiation, Cell Growth, Cell Migration, Cell Motility, Cell Proliferation, Cytolysis, Excretion, Fermentation, Glycosylation, Immune Response, Localization, Melanocyte Differentiation, Pigmentation, Secretion, Transport
Quite a number of genes have been found to play important roles in B16 Malignant Melanoma, such as CD4, CD80, CD8A, CTLA4, DCT, DCX, F10, FAM110A, FN1, IFNG, IL2, IL4, IL6, MITF, PCID2, PMEL, POMC, TNF, TYR, TYRP1. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.
In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.